ENTBF (Entheon Biomedical) Change In Receivables: $-0.12 Mil (TTM As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entheon Biomedical Change In Receivables?

Entheon Biomedical ENTBF Change In Receivables is $-0.12 Mil as of May. 2026.

Entheon Biomedical's change in receivables for the quarter that ended in May. 2026 was $-0.13 Mil. It means Entheon Biomedical's Accounts Receivable increased by $0.13 Mil from Feb. 2026 to May. 2026 .

Entheon Biomedical's change in receivables for the fiscal year that ended in Nov. 2025 was $-0.00 Mil. It means Entheon Biomedical's Accounts Receivable increased by $0.00 Mil from Nov. 2024 to Nov. 2025 .

Entheon Biomedical's Accounts Receivable for the quarter that ended in May. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Entheon Biomedical's liquidation value for the three months ended in May. 2026 was $0.21 Mil.

Entheon Biomedical  (OTCPK:ENTBF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Entheon Biomedical's Days Sales Outstanding for the quarter that ended in May. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, Entheon Biomedical's accounts receivable are only considered to be worth 75% of book value:

Entheon Biomedical's liquidation value for the quarter that ended in May. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.236-0.031+0.75 * 0+0.5 * 0
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical Change In Receivables Related Terms

Entheon Biomedical Change In Receivables Historical Data

* Premium members only.

The historical data trend for Entheon Biomedical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical Change In Receivables Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23 Nov24 Nov25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only 0.06 -0.01 0.03 0.00 -0.00

Entheon Biomedical Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 -0.00 0.00 -0.13

Entheon Biomedical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-0.12 Mil mean?
Entheon Biomedical (ENTBF) has a Change In Receivables of $-0.12 Mil as of May. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Entheon Biomedical and its competitors.
Is Entheon Biomedical's Change In Receivables too high?
Entheon Biomedical's current Change In Receivables is $-0.12 Mil.
How does Entheon Biomedical's Change In Receivables compare to VRTX and REGN?
Entheon Biomedical's Change In Receivables of $-0.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Entheon Biomedical and its competitors. Entheon Biomedical's current Change In Receivables is $-0.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current Change In Receivables of $-0.12 Mil. The current Change In Receivables is $-0.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current Change In Receivables is $-0.12 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entheon Biomedical Business Description

Other Exchanges 1XU:GermanyENBI.X:Canada
Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company focused on treating addiction and substance use disorders.